<Summary id="CDR0000812122" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of non-Hodgkin lymphoma during pregnancy.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)</SummaryURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000042673">non-Hodgkin lymphoma during pregnancy</TermRef></MainTopics><SummaryAbstract><Para id="_807">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of non-Hodgkin lymphoma during pregnancy. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_808">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>adult non-Hodgkin lymphoma</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Non-Hodgkin Lymphoma Treatment During Pregnancy</AltTitle><SummarySection id="_809"><SectMetaData><SpecificDiagnosis ref="CDR0000042673">non-Hodgkin lymphoma during pregnancy</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Non-Hodgkin Lymphoma Treatment During Pregnancy</Title><Para id="_810">Non-Hodgkin lymphoma (NHL) is more common in older patients, with a median age at diagnosis of 68 years.<Reference refidx="1"/> Hodgkin lymphoma is most common in early adulthood and in patients older than 65 years.<Reference refidx="2"/> This age distribution may explain why there are fewer reports of NHL in pregnant patients.<Reference refidx="3"/></Para><ReferenceSection><Citation idx="1">Surveillance, Epidemiology, and End Results Program: SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. 	Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program. <ExternalRef xref="https://seer.cancer.gov/statfacts/html/nhl.html">Available online</ExternalRef>. Last accessed December 16, 2024.</Citation><Citation idx="2">Surveillance, Epidemiology, and End Results Program: SEER Cancer Stat Facts: Hodgkin Lymphoma. Bethesda, Md: National Cancer Institute. <ExternalRef xref="https://seer.cancer.gov/statfacts/html/hodg.html">Available online</ExternalRef>. Last accessed December 16, 2024.</Citation><Citation idx="3" PMID="2678489" MedlineID="90019588">Ward FT, Weiss RB: Lymphoma and pregnancy. Semin Oncol 16 (5): 397-409, 1989.</Citation></ReferenceSection></SummarySection><SummarySection id="_813"><SectMetaData><SpecificDiagnosis ref="CDR0000042673">non-Hodgkin lymphoma during pregnancy</SpecificDiagnosis><SectionType>Cancer description</SectionType></SectMetaData><Title>Stage Information for Non-Hodgkin Lymphoma During Pregnancy</Title><Para id="_814">To avoid exposure to ionizing radiation, magnetic resonance imaging is the preferred tool for staging evaluation.<Reference refidx="1"/> For more information, see the <SummaryRef href="CDR0000811546#_5" url="/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq">Stage Information for Indolent B-Cell Non-Hodgkin Lymphoma</SummaryRef> section in Indolent B-Cell Non-Hodgkin Lymphoma Treatment.</Para><ReferenceSection><Citation idx="1" PMID="11130469" MedlineID="21013025">Nicklas AH, Baker ME: Imaging strategies in the pregnant cancer patient. Semin Oncol 27 (6): 623-32, 2000.</Citation></ReferenceSection></SummarySection><SummarySection id="_815"><SectMetaData><SpecificDiagnosis ref="CDR0000042673">non-Hodgkin lymphoma during pregnancy</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for Non-Hodgkin Lymphoma During Pregnancy</Title><Table id="_816"><Title>Table 1.  Treatment Options for Non-Hodgkin Lymphoma (NHL) During Pregnancy</Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">Treatment Options</entry></Row></THead><TBody><Row><entry><SummaryRef href="CDR0000812122#_817" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Indolent NHL During Pregnancy</SummaryRef></entry><entry>Delay treatment until after delivery</entry></Row><Row><entry MoreRows="2"><SummaryRef href="CDR0000812122#_819" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Aggressive NHL During Pregnancy</SummaryRef></entry><entry><SummaryRef href="CDR0000812122#_820" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Immediate therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000812122#_823" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Early delivery, when feasible</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000812122#_825" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">Termination of pregnancy</SummaryRef></entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_817"><Title>Treatment of Indolent Non-Hodgkin Lymphoma During Pregnancy</Title><Para id="_818">Treatment may be delayed for women with an indolent non-Hodgkin lymphoma.</Para></SummarySection><SummarySection id="_819"><Title>Treatment of Aggressive Non-Hodgkin Lymphoma During Pregnancy</Title><SummarySection id="_820"><Title>Immediate Therapy</Title><Para id="_821">According to anecdotal case series, most non-Hodgkin lymphomas (NHLs) in pregnant patients are aggressive, and delay of therapy until after delivery appears to have poor outcomes.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> Consequently, some investigators favor immediate therapy, even during pregnancy.<Reference refidx="4"/> In a review of 121 patient case reports from 74 papers, one-half of the patients had very aggressive lymphomas, such as Burkitt lymphoma, and one-half of the patients had involvement of the breast, ovaries, uterus, or placenta.<Reference refidx="5"/> One-half of the patients received therapy antepartum, and the 6-month survival rate was 53%, with a live-birth rate of 83%.<Reference refidx="5"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</Para><Para id="_822">A multicenter retrospective analysis of 50 patients described pregnancy termination in 3 patients, deferral of therapy to postpartum in 15 patients (median 30 weeks gestation), and antenatal therapy in the remaining 32 patients  (median 21 weeks gestation, all done after the first trimester).<Reference refidx="6"/> With a median follow-up of 41 months, the 3-year progression-free survival  rate was 53%, and the overall survival rate was 82%, using R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) or modifications of this regimen.<Reference refidx="6"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</Para></SummarySection><SummarySection id="_823"><Title>Early Delivery, When Feasible</Title><Para id="_824">For some women, early delivery, when feasible, may minimize or avoid fetal exposure to chemotherapy or radiation therapy.</Para></SummarySection><SummarySection id="_825"><Title>Termination of Pregnancy</Title><Para id="_826">Termination of pregnancy in the first trimester may allow immediate therapy for women with aggressive NHL.</Para></SummarySection><SummarySection id="_830"><Title>Effects of Treatment on Children</Title><Para id="_827">Evidence (treatment effect on children exposed in utero):</Para><ItemizedList id="_828" Style="bullet">
     <ListItem>With follow-up ranging from several months to 11 years, children who were exposed to high-dose doxorubicin-containing combination chemotherapy in utero (especially during the second and third trimester) had normal growth and no evidence of congenital malformations.<Reference refidx="4"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/> For most of the chemotherapeutic agents used for the treatment of NHL, there are no data regarding long-term effects on children exposed in utero.</ListItem><ListItem>In one anecdotal case, a newborn exposed to a rituximab-containing regimen in utero was born with no circulating B lymphocytes. The newborn was otherwise healthy and recovered the circulating B lymphocytes by age 6 months with no unusual or persisting intercurrent infections.<Reference refidx="10"/> </ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="2678489" MedlineID="90019588">Ward FT, Weiss RB: Lymphoma and pregnancy. Semin Oncol 16 (5): 397-409, 1989.</Citation><Citation idx="2" PMID="4027936" MedlineID="85282110">Steiner-Salz D, Yahalom J, Samuelov A, et al.: Non-Hodgkin's lymphoma associated with pregnancy. A report of six cases, with a review of the literature. Cancer 56 (8): 2087-91, 1985.</Citation><Citation idx="3" PMID="1752504" MedlineID="92090806">Spitzer M, Citron M, Ilardi CF, et al.: Non-Hodgkin's lymphoma during pregnancy. Gynecol Oncol 43 (3): 309-12, 1991.</Citation><Citation idx="4" PMID="8674008" MedlineID="96284299">Gelb AB, van de Rijn M, Warnke RA, et al.: Pregnancy-associated lymphomas. A clinicopathologic study. Cancer 78 (2): 304-10, 1996.</Citation><Citation idx="5" PMID="23725710">Horowitz NA, Benyamini N, Wohlfart K, et al.: Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review. Lancet Oncol 14 (7): e275-82, 2013.</Citation><Citation idx="6" PMID="24043736">Evens AM, Advani R, Press OW, et al.: Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31 (32): 4132-9, 2013.</Citation><Citation idx="7" PMID="2351317" MedlineID="90276920">Avilés A, Díaz-Maqueo JC, Torras V, et al.: Non-Hodgkin's lymphomas and pregnancy: presentation of 16 cases. Gynecol Oncol 37 (3): 335-7, 1990.</Citation><Citation idx="8" PMID="1921384" MedlineID="92016435">Moore DT, Taslimi MM: Multi-agent chemotherapy in a case of non-Hodgkin's lymphoma in second trimester of pregnancy. J Tenn Med Assoc 84 (9): 435-6, 1991.</Citation><Citation idx="9" PMID="1689451" MedlineID="90158359">Nantel S, Parboosingh J, Poon MC: Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy. Med Pediatr Oncol 18 (2): 143-5, 1990.</Citation><Citation idx="10" PMID="24562617">Mandal PK, Dolai TK, Bagchi B, et al.: B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr 81 (10): 1092-4, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_811"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (02/18/2025)</Title><Para id="_812">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_829">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000812122#_AboutThis_1" url="/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of non-Hodgkin lymphoma during pregnancy. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Non-Hodgkin Lymphoma Treatment During Pregnancy are:</Para><ItemizedList Style="bullet"><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem><ListItem>Cole H. Sterling, MD (Johns Hopkins University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Non-Hodgkin Lymphoma Treatment During Pregnancy. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq">https://www.cancer.gov/types/lymphoma/hp/non-hodgkin-lymphoma-treatment-during-pregnancy-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 37437081]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2023-06-26</DateFirstPublished><DateLastModified>2025-02-18</DateLastModified></Summary>
